All News

If members of the Medicare Payment Advisory Commission have their way, the new Merit-based Incentive Payment System will be sent into oblivion, never to be heard of again.

In this interview, urologist Francis J. McGovern, MD, discusses the scope of the problem of opioid abuse, outlines opioid-sparing strategies, and explains what the future holds in this area.

In men with clinically low-risk prostate cancer managed in community-based urology practices, utilization of active surveillance as initial management is higher among those who undergo genomic testing.

Use of a cell cycle progression genomics test (Prolaris) can further stratify risk in men who are candidates for active surveillance based on clinical criteria, and therefore may have a role in decision-making in men with early-stage prostate cancer, researchers say.

Results of one of the first randomized controlled trials evaluating cell therapy for women with stress urinary incontinence (SUI) has helped to identify clinically meaningful efficacy endpoints to refine patient selection criteria for current and future studies, according to investigator Melissa R. Kaufman, MD, PhD.

Adding ramucirumab (CYRAMZA) to standard docetaxel (Taxotere) improved progression-free survival compared with docetaxel alone in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy.